He L, Li J, Cheng X, Luo L, Huang Y. Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. Front Pharmacol. 2025;16:1509561. https://doi.org/10.3389/fphar.2025.1509561.

Article  CAS  PubMed  Google Scholar 

Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172:108656. https://doi.org/10.1016/j.diabres.2021.108656.

Article  CAS  PubMed  Google Scholar 

Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002. https://doi.org/10.1124/pharmrev.123.001045.

Article  PubMed  Google Scholar 

Arredouani A. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Pharmacol Ther. 2025;269:108824. https://doi.org/10.1016/j.pharmthera.2025.108824.

Article  CAS  PubMed  Google Scholar 

Lee MMY, Ghouri N, Misra A, et al. Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in Asian versus White populations: systematic review and meta-analysis of randomized trials of populations with or without type 2 diabetes and/or overweight or obesity. Diabetes Care. 2025;48(3):489–93. https://doi.org/10.2337/dc24-1533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol. 2022;21(1):64. https://doi.org/10.1186/s12933-022-01489-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44(1):14–32. https://doi.org/10.1210/endrev/bnac018.

Article  PubMed  Google Scholar 

Lyu Q, Ye P, Zhang H, et al. Safety of sugammadex for reversal of neuromuscular block: a postmarketing study based on the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2023;89(2):449–57. https://doi.org/10.1111/bcp.15417.

Article  CAS  PubMed  Google Scholar 

Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022;28(1):89–95. https://doi.org/10.1038/s41591-021-01584-3.

Article  CAS  PubMed  Google Scholar 

Hannon TS, Chao LC, Barrientos-Pérez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2025;406(10511):1484–96. https://doi.org/10.1016/S0140-6736(25)01774-X.

Article  CAS  PubMed  Google Scholar 

Pak KY, Cutri RM, Nadeem W, et al. GLP-1 receptor agonist induced Eustachian tube dysfunction: database and systematic review of otolaryngologic adverse events. Otol Neurotol. 2025;46(1):19–22. https://doi.org/10.1097/MAO.0000000000004373.

Article  PubMed  Google Scholar 

Patti AM, Giglio RV, Allotta A, et al. Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes. Biomedicines. 2023;11(5):1362. https://doi.org/10.3390/biomedicines11051362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizzo M, Nikolic D, Banach M, Patti A, Montalto G, Rizvi A. Incretin-based therapies, glucometabolic health and endovascular inflammation. CPD Contin Prof Dev. 2014;20(31):4953–60. https://doi.org/10.2174/1381612819666131206102255.

Article  CAS  Google Scholar 

Nikolic D, Patti AM, Giglio RV, et al. Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study. Diabetes Ther. 2022;13(3):453–64. https://doi.org/10.1007/s13300-022-01217-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clin Lipidol. 2013;8(6):659–67. https://doi.org/10.2217/clp.13.67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointest Endosc. 2025;101(4):762-771.e13. https://doi.org/10.1016/j.gie.2024.12.019.

Article  PubMed  Google Scholar 

Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789. https://doi.org/10.3389/fendo.2022.1043789.

Article  Google Scholar 

Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: a pharmacovigilance analysis based on the Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2025;91(4):1272–80. https://doi.org/10.1111/bcp.16354.

Article  CAS  PubMed  Google Scholar 

Song Q, Gao S, Tan Y. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. J Headache Pain. 2025;26(1):147. https://doi.org/10.1186/s10194-025-02091-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X. Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine. 2024;88(1):80–90. https://doi.org/10.1007/s12020-024-04112-8.

Article  CAS  PubMed  Google Scholar 

Breit S, Hubl D. The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: a systematic review. Psychoneuroendocrinology. 2025;176:107415. https://doi.org/10.1016/j.psyneuen.2025.107415.

Article  CAS  PubMed  Google Scholar 

Madsen JM, Kjaer AK, Lønborg JT, et al. Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2025;24(1):4. https://doi.org/10.1186/s12933-024-02548-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167(4):689–703. https://doi.org/10.1053/j.gastro.2024.04.029.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guirguis A, Chiappini S, Papanti PG, et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024;82:82–91. https://doi.org/10.1016/j.euroneuro.2024.02.003.

Article  CAS  PubMed  Google Scholar 

Wang M, Chen X, Liu Z, et al. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. eClinicalMedicine. 2025;86:103385. https://doi.org/10.1016/j.eclinm.2025.103385.

Article  PubMed  PubMed Central  Google Scholar 

Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949–61. https://doi.org/10.1016/S0140-6736(24)01643-X.

Article  CAS  PubMed  Google Scholar 

Jung HN, Jung CH. The upcoming weekly tides (semaglutide vs. tirzepatide) against obesity: STEP or SURPASS? J Obes Metab Syndr. 2022;31(1):28–36. https://doi.org/10.7570/jomes22012.